Countries are at different stages of introducing already approved PrEP, and more PrEP products are coming. Some countries have national programs, others have smaller-scale programs, others aren’t yet offering PrEP at all. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not.
Want to take the next step in expanding access to PrEP? Check out PrEP Planning A-Z.
This framework outlines the steps involved to introduce oral PrEP as a model for scaling up biomedical HIV prevention products—with links to tools and resources.
Two views of PrEP uptake around the world: The PrEP Tracker as data visualization—a dynamic map exploring global trends
The PrEP Tracker in Excel—details on the full scope of programs in every country
A guide for stakeholders preparing for the rollout of the ring to coordinate and streamline access to the ring everywhere it’s needed.
Stories from implementers rolling out PrEP: a look at some real world obstacles and the tools and insights to overcome them.
A combination of two injectable drugs will provide an alternative to daily pills for people with HIV.
The Prevention Product Manager (PMM) and Jhpiego convened think tanks to discuss options for defining and measuring PrEP continuation. Recommendations from the think tank included modifications to current PrEP indicators, recognizing that a single definition of correct or effective use might not be possible given fluctuating and variable HIV risk.
AVAC enthusiastically welcomes the news that another trial of the long-acting, injectable antiretroviral cabotegravir (CAB-LA) for HIV prevention for HIV pre-exposure prophylaxis (PrEP) has demonstrated safety and efficacy, this time among cisgender women.